As a result, ANA will be the first U.S.-based company to conduct a human clinical trial for determining the efficacy of niclosamide in treating COVID-19, according to the firm. The clinical trial will seek to enroll at least 400 COVID-19 patients at 10 centers in the U.S., specifically in states such as Florida and Texas that are experiencing surges in cases.

In the trial, ANA will evaluate the safety of niclosamide, as well as its ability to demonstrate a clinical improvement in hospitalized COVID-19 patients. The study will focus on patients with less-severe symptoms who are not on ventilators, according to the company.

Patients will be given a seven-day course of niclosamide and monitored for 60 days. The first patient is expected to be enrolled in August. The firm said it also plans to assess niclosamide's effectiveness in treating outpatients in a later study.

NIH launches clinical trial for COVID-19 antibody treatment
The National Institutes of Health (NIH) has started enrolling volunteers in a phase III randomized, controlled clinical trial to test multiple monoclonal...

NIH leads adaptive phase II clinical trial for COVID-19 mAb
The National Institutes of Health (NIH) is now studying an investigational monoclonal antibody (mAb), Ly-CoV555, as part of an adaptive phase II clinical...

Study analyzes how SARS-CoV-2 undermines immune defenses
A new research study used whole-genome sequencing to analyze the genetic profile of patients with the SARS-CoV-2 virus to gain more insight into how it...

Neutrolis develops new COVID-19 treatment
Neutrolis has developed a new class of COVID-19 therapy, a DNASEIL3 enzyme analog that has the potential to clear neutrophil extracellular traps for severe...

R&D Alliance begin I-Spy COVID trial
A collaborative research effort that includes the U.S. government and leading pharmaceutical companies has launched a clinical trial to investigate a...